Understanding the relationship between biotherapeutic protein stability and solid-liquid interfacial shear in constant region mutants of IgG1 and IgG4

Journal of Pharmaceutical Sciences

Volumn 103, Issue 2, 2014, Pages 437-444

  Tavakoli Keshe, Roumteen ^a,b   Phillips, Jonathan J ^b   Turner, Richard ^b   Bracewell, Daniel G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MEDIMMUNE   (United States)

Author keywords

Biopharmaceuticals characterization; Calorimetry (DSC); IgG antibody; In silico modeling; Molecular modeling; Protein aggregation; Protein structure; Thermal analysis

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G4 ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANALYTICAL EQUIPMENT; ANTIBODY STRUCTURE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN CONSTANT REGION; LIQUID; MELTING POINT; MOLECULAR INTERACTION; MOLECULAR MODEL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN STABILITY; SHEAR STRESS; SOLID; SURFACE CHARGE; THERMOSTABILITY;

BIOPHARMACEUTICALS CHARACTERIZATION; CALORIMETRY (DSC); IGG ANTIBODY; IN SILICO MODELING; MOLECULAR MODELING; PROTEIN AGGREGATION; PROTEIN STRUCTURE; THERMAL ANALYSIS;

ANTIBODIES, MONOCLONAL; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; DRUG STABILITY; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MODELS, MOLECULAR; MOLECULAR WEIGHT; PROTEIN STABILITY; PROTEINS; SPECTROPHOTOMETRY, ULTRAVIOLET; SURFACE PROPERTIES; TEMPERATURE;

EID: 84895924014     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23822     Document Type: Article

References (54)

1. Jimenez M, Rivas Gn, Minton AP. 2007. Quantitative characterization of weak self-association in concentrated solutions of immunoglobulin G via the measurement of sedimentation equilibrium and osmotic pressure. Biochemistry 46(28):8373-8378.
2. Bee JS, Goletz TJ, Ragheb JA. 2012. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: A shared perspective. J Pharm Sci 101(10):3580-3585.
3. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V. 2012. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287(30):25266-25279.
4. Lehr H-A, Brunner J, Rangoonwala R, James Kirkpatrick C. 2002. Particulatematter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. Am J Respir Crit Care Med 165(4):514-520.
5. Rosenberg A. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8(3):E501-E507.
6. PE. 2008. European directorate for the quality of medicine. Particulate contamination: Subivisible particles.
7. USP. 2008. United States Pharmacopoeial Convention USP 2008.
8. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan Y-X, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98(4):1201-1205.
9. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. 2010. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99(4):1707-1720.
10. Fasman GD. 1996. Circular dichrosm and the conformational analysis of biomolecules. New York: Plenum Press.
11. Lednev IK, Shashilov V, Xu M. 2009. Ultraviolet Raman spectroscopy is uniquely suitable for studying amyloid diseases. Curr Sci 97(2):180.
12. Hammes GG. 2005. Mass spectrometry. Spectroscopy for the biological sciences. New Jersey: John Wiley & Sons, Inc., pp 145-162.
13. Biddlecombe JG, Craig AV, Zhang H, Uddin S, Mulot S, Fish BC, Bracewell DG. 2007. Determining antibody stability: Creation of solid- liquid interfacial effects within a high shear environment. Biotechnol Progr 23(5):1218-1222.
14. Dasnoy S, Dezutter N, Lemoine D, Le Bras V, Praat V. Highthroughput screening of excipients intended to prevent antigen aggregation at air-liquid interface. Pharm Res 28(7):1591-1605.
15. Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. 2011. Classification and characterization of therapeutic antibody aggregates. J Biol Chem 286(28):25118-25133.
16. Bee JS, Chiu D, Sawicki S, Stevenson JL, Chatterjee K, Freund E, Carpenter JF, Randolph TW. 2009. Monoclonal antibody interactions with micro- and nanoparticles: Adsorption, aggregation, and accelerated stress studies. J Pharm Sci 98(9):3218-3238.
17. Thomas C, Geer D Effects of shear on proteins in solution. Biotechnol Lett 33(3):443-456.
18. Hawe A, Kasper JC, Friess W, Jiskoot W. 2009. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci 38(2):79-87.
19. Kiese S, Papppenberger A, Friess W, Mahler H-C. 2008. Shaken, not stirred: Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97(10):4347-4366.
20. Bekard IB, Dunstan DE. 2009. Shear-induced deformation of bovine insulin in Couette flow. J Phys Chem B 113(25):8453-8457.
21. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 20(9):1325-1336.
22. Bee JS, Stevenson JL, Mehta B, Svitel J, Pollastrini J, Platz R, Freund E, Carpenter JF, Randolph TW. 2009. Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng 103(5):936-943.
23. Mahler H-C, Maller R, Friei W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 59(3):407-417.
24. Ashton L, Dusting J, Imomoh E, Balabani S, Blanch EW. 2009. Shear-induced unfolding of lysozyme monitored in situ. Biophys J 96(10):4231-4236.
25. Cromwell ME, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing. AAPS J 8(3):E572-E579.
26. Maa Y-F, Hsu CC. 1996. Effect of high shear on proteins. Biotechnol Bioeng 51(4):458-465.
27. Bee JS, Davis M, Freund E, Carpenter JF, Randolph TW. 2010. Aggregation of a monoclonal antibody induced by adsorption to stainless steel. Biotechnol Bioeng 105(1):121-129.
28. Biddlecombe JG, Smith G, Uddin S, Mulot S, Spencer D, Gee C, Fish BC, Bracewell DG. 2009. Factors influencing antibody stability at solid-liquid interfaces in a high shear environment. Biotechnol Progr 25(5):1499-1507.
29. Wang L, Ghosh R. 2009. Feasibility study for the fractionation of the major human immunoglobulin G subclasses using hydrophobic interaction membrane chromatography. Anal Chem 82(1):452-455.
30. Janeway CA. 2001. Immunobiology. New York: Garland Publisher.
31. Aalberse RC, van der Gaag R, van Leeuwen J. 1983. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4- restricted response. J Immunol 130(2):722-726.
32. Aalberse RC, Schuurman J. 2002. IgG4 breaking the rules. Immunology 105(1):9-19.
33. van der Zee JS, van Swieten P, Aalberse RC. 1986. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 137(11):3566-3571.
34. Lu Y, Harding SE, Michaelsen TE, Longman E, Davis KG, Ortega Á, Grossmann JG, Sandlie I, Garća de la Torre J. 2007. Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: Possible implications for complement activation. Biophys J 93(11):3733-3744.
35. Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, Oi VT. 1988. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 7(7):1989-1994.
36. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H. 2006. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 177(2):1129-1138.
37. Kilar F, Simon I, Lakatos S, Vonderviszt F, Medgyesi GA, Zavodszky P. 1985. Conformation of human IgG subclasses in solution. Smallangle X-ray scattering and hydrodynamic studies. Eur J Biochem 147(1):17-25.
38. Heads JT, Adams R, D'Hooghe LE, Page MJ, Humphreys DP, Popplewell AG, Lawson AD, Henry AJ. 2012. Relative stabilities of IgG1 and IgG4 Fab domains: Influence of the light-heavy interchain disulfide bond architecture. Protein Sci 21(9):1315-1322.
39. Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall'Acqua WF. 2009. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 46(8-9):1750-1755.
40. Dall'Acqua WF, Kiener PA, Wu H. 2006. Properties of Hhuman IgG1s Eengineered for Eenhanced Bbinding to the Nneonatal Fc Rreceptor (FcRn). J Biol Chem 281(33):23514-23524.
41. Brummitt RK, Nesta DP, Chang L, Chase SF, Laue TM, Roberts CJ. 2011. Nonnative aggregation of an IgG1 antibody in acidic conditions: Part 1. Unfolding, colloidal interactions, and formation of highmolecular- weight aggregates. J Pharm Sci 100(6):2087-2103.
42. Roberts CJ. 2007. Non-native protein aggregation kinetics. Biotechnol Bioeng 98(5):927-938.
43. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL. 2009. Aggregation-prone motifs in human immunoglobulin G. J Mol Biol 391(2):404-413.
44. Sasahara K, Yagi H, Sakai M, Naiki H, Goto Y. 2008. Amyloid nucleation triggered by agitation of 122-microglobulin under acidic and neutral pH conditions. Biochemistry 47(8):2650-2660.
45. Kim Y-S, Randolph TW, Stevens FJ, Carpenter JF. 2002. Kinetics and energetics of assembly, nucleation, and growth of aggregates and fibrils for an amyloidogenic protein. J Biol Chem 277(30) 27240-27246.
46. Tischenko VM, Zav'Yalov VP, Medgyesi GA, Potekhin SA, Privalov PL. 1982. A thermodynamic study of cooperative structures in rabbit immunoglobulin G. Eur J Biochem 126(3):517-521.
47. Privalov PL, Potekhin SA. 1986. Scanning microcalorimetry in studying temperature-induced changes in proteins. Methods Enzymol 131:4-51.
48. Gill P, Moghadam TT, Ranjbar B. 2010. Differential scanning calorimetry techniques: Applications in biology and nanoscience. J Biomol Tech 21(4):167-193.
49. Vermeer AWP, Norde W. 2000. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys J 78(1):394-404.
50. Fesinmeyer R, Hogan S, Saluja A, Brych S, Kras E, Narhi L, Brems D, Gokarn Y. 2009. Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies. Pharm Res 26(4):903-913.
51. Ishikawa T, Ito T, Endo R, Nakagawa K, Sawa E, Wakamatsu K. 2010. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies. Biol Pharm Bull 33(8):1413-1417.
52. Sela Culang I, Alon S, Ofran Y. 2012. A systematic comparison of free and bound antibodies reveals binding-related conformational changes. J Immunol 189(10):4890-4899.
53. Saphire EO. 2012. Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design. Science 293:1155-1158.
54. Zurdo J. 2013. Developability assessment as an early de-risking tool for biopharmaceutical development. Pharm Bioprocess 1(1):29-50.